Journal article icon

Journal article

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

Abstract:

BACKGROUND: Evidence is scarce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and no randomised trials have been reported. We aimed to compare gefitinib with placebo in previously treated advanced oesophageal cancer. METHODS: For this phase 3, parallel, randomised, placebo-controlled trial, eligible patients were adults with advanced oesophageal cancer or type I/II Siewert junctional tumours, histologically confirmed squamous-cell carcinoma or adenoc...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1016/s1470-2045(14)70024-5

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS, CSM
Blazeby, JM More by this author
Dahle-Smith, A More by this author
Expand authors...
Cancer Research UK More from this funder
University of Oxford More from this funder
Royal Wolverhampton Hospitals NHS Trust More from this funder
Publisher:
Elsevier Publisher's website
Journal:
The Lancet. Oncology Journal website
Volume:
15
Issue:
8
Pages:
894-904
Publication date:
2014-06-17
DOI:
EISSN:
1474-5488
ISSN:
1470-2045
URN:
uuid:19906f31-3e43-443f-8b17-12f92a865d95
Source identifiers:
470727
Local pid:
pubs:470727

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP